Innate shares crushed on second big setback for Bristol-Myers partnered lirilumab
Innate Pharma is suffering through its second big setback of the year on its lead cancer drug lirilumab. Back in February the French biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
